Tag: Statin interaction

The incidence of myopathy with fibrate monotherapy is estimated to be between 0.1% and 0.5% [1.2.1]. While relatively rare, the question of 'Do fibrates cause myopathy?' is a critical one for patients managing high triglyceride levels.

Rhabdomyolysis is a rare but serious adverse event associated with fenofibrate monotherapy, where skeletal muscle breaks down and releases toxic intracellular components into the bloodstream [1.2.3, 1.2.4]. Can fenofibrate cause rhabdomyolysis? Yes, especially in patients with specific risk factors.